|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome and epigenome wide studies of neurological protein biomarkers in the Lothian Birth Cohort 1936.
|
31320639 |
2019 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genomic atlas of the human plasma proteome.
|
29875488 |
2018 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Co-regulatory networks of human serum proteins link genetics to disease.
|
30072576 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide haplotype association study identify the FGFR2 gene as a risk gene for acute myeloid leukemia.
|
27903959 |
2017 |
|
Neoplasms
|
0.070 |
PosttranslationalModification
|
group |
BEFREE |
Pyrosequencing was used to quantify ADAM23 methylation in tumors of 203 BC patients.
|
30815959 |
2019 |
|
Neoplasms
|
0.070 |
PosttranslationalModification
|
group |
BEFREE |
We detected the significant association between reduced DNA methylation of ADAM23 in PTs and presence of CTCs in the peripheral blood of patients (OR = 0.45; 95% CI, 0.23-0.90; P = 0.023).
|
30189837 |
2018 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Here, we show that invasive breast tumors exhibit significant ADAM23-ITH and that this heterogeneity is critical for tumor growth and metastasis.
|
24662834 |
2015 |
|
Neoplasms
|
0.070 |
PosttranslationalModification
|
group |
BEFREE |
The ADAM23 gene is frequently silenced in different types of tumors, and, in breast tumors, silencing is correlated with tumor progression, suggesting that it might be associated with the acquisition of a metastatic phenotype.
|
19549921 |
2009 |
|
Neoplasms
|
0.070 |
GeneticVariation
|
group |
BEFREE |
In the oropharynx, there was a statistically significant association between hypermethylation of the DAPK1 gene and the occurrence of lymph node metastases, and in the larynx there was statistically significant evidence of an association between hypermethylation of the ADAM23 gene and advanced stages of the tumors.
|
17284367 |
2007 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Methylation of this CpG island was observed both in GC cell lines and in primary GC tissues; in primary tumors with a hypermethylated CpG island, expression of ADAM23 was lower than in adjacent noncancerous tissues.
|
16103878 |
2005 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
We found ADAM23 5' hypermethylation in eight out of 12 (66.7%) tumor cell lines and in nine out of 13 (69.2%) primary tumors.
|
14661055 |
2004 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
ADAM23 is considered a possible tumor suppressor gene and is frequently downregulated in various types of malignancies.
|
30815959 |
2019 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
A Disintegrin And Metalloprotease 23 (ADAM23), a member of the ADAM family, is involved in neuronal differentiation and cancer.
|
30815959 |
2019 |
|
Malignant Neoplasms
|
0.050 |
GeneticVariation
|
group |
BEFREE |
The relationships between the decreased methylation levels of the SNAI2 and ADAM23 genes and cancer de-differentiation and haematogenous dissemination, respectively, indicate novel functions of those genes in the invasive processes.
|
30189837 |
2018 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
A disintegrin and metalloprotease 23 (ADAM23), a member of ADAM family, is involved in cancer and neuronal differentiation.
|
30371220 |
2018 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
A disintegrin and metalloprotease 23 (ADAM23), a member of ADAM family, is involved in cancer and neuronal differentiation.
|
30371220 |
2018 |
|
Primary malignant neoplasm
|
0.050 |
GeneticVariation
|
group |
BEFREE |
The relationships between the decreased methylation levels of the SNAI2 and ADAM23 genes and cancer de-differentiation and haematogenous dissemination, respectively, indicate novel functions of those genes in the invasive processes.
|
30189837 |
2018 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Our data provide evidence that ADAM23 plays a role in suppression of cancer cell progression through interaction with αvβ3 integrin, and suggest that downregulation of ADAM23 in SP cells may contribute toward providing a cancer stem cell phenotype by facilitating the activity of integrin αvβ3.
|
26800504 |
2016 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
Our data provide evidence that ADAM23 plays a role in suppression of cancer cell progression through interaction with αvβ3 integrin, and suggest that downregulation of ADAM23 in SP cells may contribute toward providing a cancer stem cell phenotype by facilitating the activity of integrin αvβ3.
|
26800504 |
2016 |
|
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemistry and RT-PCR together with Western blotting methods were used to analyse the expression of ADAM23 in 52 cancer tissue samples and eight benign pulmonary lesions as well as four cell lines.
|
21429053 |
2011 |
|
Primary malignant neoplasm
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemistry and RT-PCR together with Western blotting methods were used to analyse the expression of ADAM23 in 52 cancer tissue samples and eight benign pulmonary lesions as well as four cell lines.
|
21429053 |
2011 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our results indicate that ADAM23 is likely involved in BC progression and dissemination of mesenchymal CTC.
|
30815959 |
2019 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our results indicate that ADAM23 is likely involved in BC progression and dissemination of mesenchymal CTC.
|
30815959 |
2019 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
Decreased methylation in the SNAI2 and ADAM23 genes associated with de-differentiation and haematogenous dissemination in breast cancers.
|
30189837 |
2018 |
|
Breast Carcinoma
|
0.040 |
PosttranslationalModification
|
disease |
BEFREE |
After experimental validation of the association between the lower values of SNAI2 and ADAM23 methylation and clinical features of aggressive BCs, these methylation profiles could improve the management of metastatic disease.
|
30189837 |
2018 |